Wilson's disease
ICD-10 E83.0 · ICD-11 5C64.00
Next-line protocol · Asymptomatic

Wilson's Disease in Asymptomatic Patients When First-Line Zinc or Chelation Therapy Has Not Reached Target

Some asymptomatic patients with Wilson's disease — with no signs of significant liver involvement — do not achieve the required copper control goals on their initial treatment. This protocol defines the structured next step when that happens.

Clinical Scenario

The patient is asymptomatic with no signs of significant liver involvement. Either zinc or chelator therapy may be used in this population; zinc salts are typically the first-line choice. This protocol applies when that first-line regimen — despite adequate adherence — has not achieved the required maintenance targets, or when side effects prevent continuation.

Previous Treatment Did Not Achieve Targets

The prior treatment line uses zinc or chelators. On zinc maintenance, the following goals must be reached:

Failure to reach these targets despite good adherence — or the development of side effects — is the trigger for escalation to this protocol.

Treatment Direction (Summary Only)

The approach involves switching to a different treatment. The specific agents considered, their selection criteria, and how the transition is managed are detailed in the full structured protocol — only a partial indication is given here.

Treatment Goals

The primary measure of success is 24-h urinary copper excretion falling within the established maintenance target range for the specific chelator used. Exact numeric thresholds and monitoring schedules are specified in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. Either zinc or chelators may be used in asymptomatic patients without signs of significant liver involvement (LoE 4, weak recommendation, consensus).
  2. In patients with WD who do not achieve sufficient treatment response on first-line therapy despite a good adherence to treatment and a 24-h urinary copper excretion in the target range, or side effects, switching treatment should be considered (D-penicillamine to trientine and vice versa or zinc to chelators) (LoE 2, strong recommendation, strong consensus).
  3. 24-h urinary copper excretion: 200–500 µg (3–8 µmol)/24 h on maintenance treatment.
DOI: 10.1016/j.jhep.2024.11.007
View source ↗